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TITLE OF THE STUDY 
 
A prospective, single arm, open trial to assess the safety and efficacy of 
fondaparinux in unstable angina and non-ST elevation myocardial infarction 
compared to historical controls treated with enoxaparin. 
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ABSTRACT 
 
Background: The OASIS-5 trial demonstrated that fondaparinux was noninferior to 
enoxaparin while reducing the risk of bleeding by 50%. The objective of our study was to 
assess the effects of fondaparinux in patients with unstable angina or NSTEMI compared to 
historical controls treated with enoxaparin. This study is designed to assess the utility of 
fondaparinux in our current clinical practice. 
Methods: We prospectively included 40 patients with unstable angina or NSTEMI to 
receive fondaparinux (2.5 mg daily) for a mean duration of 5 days and evaluated the 
composite of death, myocardial infarction, or refractory ischemia at 30 days as the primary 
efficacy outcome and major bleeding or stroke at 1 month as the primary safety outcome. 
Historical controls included 44 patients treated with enoxaparin 1mg/kg twice daily. 
Results: The effect of fondaparinux versus enoxaparin on the primary composite outcome 
of death, myocardial infarction, and refractory ischemia at 30 days was similar (27.5% 
versus 34% p=0.51). The differences in rates of death or refractory ischemia at 30 days 
between the 2 groups were also not statistically significant (5% versus 6.8%, p=0.72 and 
22.5% versus 27.2%, p=0.61). There was no documented myocardial infarction, major or 
minor bleeding or stroke during the study period.  There was a non-significant trend toward 
a lower 1 week mortality in the fondaparinux group (0% vs. 6.8%, P=0.09). The rate of 
revascularization procedures at 1 month was similar between the 2 groups. When 
compared to OASIS 5 trial, patients in our study had more frequent hospitalizations for 
refractory ischemia but less revascularization procedures. 
Conclusion:  In this study fondaparinux was found not superior to enoxaparin in the 
treatment of unstable angina/NSTEMI when primary composite outcome measures are 
compared at 1 month. Expected reduction in major/minor bleeding and stroke with 
fondaparinux was not found in this trial. This is likely to be due to small number of patients 
and low rates of revascularization procedures.  
 
7 
 
INTRODUCTION 
 
Unstable angina/non-ST elevation myocardial infarction (UA/NSTEMI) constitutes a clinical 
syndrome subset of acute coronary syndrome (ACS) that is usually, but not always, caused 
by atherosclerotic coronary artery disease (CAD) and is associated with an increased risk 
of cardiac death and subsequent myocardial infarction. In the spectrum of acute coronary 
syndrome, UA/NSTEMI is defined by ECG ST-segment depression or prominent T-wave 
inversion and/or positive biomarkers of necrosis in the absence of ST-segment elevation 
and in an appropriate clinical setting (chest discomfort or anginal equivalent) 1.  
 
UA and NSTEMI are considered to be closely related conditions whose pathogenesis and 
clinical presentations are similar but of differing severity, that is, whether the ischemia is 
severe enough to cause myocardial injury with the release of a marker of myocardial injury. 
The appearance of these biomarkers may be delayed by up to several hours after the onset 
of ischemic symptoms, after which the differentiation between UA and NSTEMI (i.e., 
elevated biomarkers) can be made definitively.2  
 
Anticoagulant therapy is essential to modify the ACS disease process and its adverse 
consequences. A combination of aspirin, an anticoagulant, and additional antiplatelet 
therapy represents the most effective therapy.3,4 The intensity of treatment is tailored to 
individual risk, and triple-anticoagulant treatment is used in patients with continuing 
ischemia or with other high-risk features and in patients oriented to an early invasive 
strategy.1  
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An increasing number of anticoagulants (previously referred to as antithrombins) have 
become available for management of patients with UA/NSTEMI. Although each agent or 
regimen reviewed (un-fractionated heparin[UFH] , enoxaparin, fondaparinux, and 
bivalirudin [invasive strategy only]) satisfies criteria for effectiveness, it is often difficult to 
conclude that one antithrombotic strategy is preferred over another, given differing study 
designs (blinded vs. unblinded; superiority vs. noninferiority) and questions of equipotent 
dosing; differing patient populations (higher vs. lower risk), durations of therapy, and 
strategies (invasive vs. conservative); confounding by open-label and crossover use of 
anticoagulants; differing antiplatelet strategies; and differing study protocols.1  
 
Unfractionated heparin accelerates the action of circulating antithrombin, which inactivates 
factor IIa (thrombin), factor IXa, and factor Xa. Unfractionated heparin prevents thrombus 
propagation and prevents early ischemic events. Most of the benefit is short term, with 
reactivation of the thrombotic process (“rebound”) after the discontinuation of UFH 
contributing to the loss of early gain.5 
 
Low-molecular weight heparin(LMWHs) have been widely tested as a means of improving 
on anticoagulation with UFH. These agents combine factor IIa and factor Xa inhibition and 
thus inhibit both the action and generation of thrombin. Advantages of LMWH over UFH 
include decreased binding to plasma proteins and endothelial cells and dose-independent 
clearance, with a longer half-life. This results in more predictable and sustained 
anticoagulation with once- or twice-a-day subcutaneous administration that usually does 
not require laboratory monitoring.6  
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Unstable angina/NSTEMI trials of LMWH and ASA compared with ASA alone or with UFH  
have generally shown favorable results. The incremental benefit of enoxaparin over UFH  
shown in certain trials appeared to be driven largely by a reduction in nonfatal MI. 7 
 
The contemporary practice of using double anti-platelet agents, an anti-thrombotic agent and  
an invasive strategy have substantially reduced ischemic events, but increased the rate  
of bleeding. Given that major bleeding has  serious long-term consequences,  
treatment strategies that reduce the risk of bleeding while maintaining or enhancing the  
benefits of reduced ischemic events are required. Fondaparinux is an important step toward  
such strategy.8  
 
Fondaparinux, a synthetic pentasaccharide, selectively binds antithrombin III and causes rapid  
and predictable inhibition of factor Xa. Previous studies (OASIS 5) showed that fondaparinux  
and enoxaparin have similar short term efficacy, fondaparinux substantially reduces bleeding  
and the reduced bleeding and that accompanies the use of fondaparinux is associated with  
lower long-term mortality and morbidity.  In addition there were significantly fewer strokes  
with fondaparinux than with enoxaparin.8 
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AIM AND OBJECTIVE 
 
AIM: 
The aim of the study is to assess the safety and efficacy of fondaparinux in patients with  
unstable  angina and myocardial infarction without ST elevation. 
 
OBJECTIVE: 
The objective of our study was to assess the effects of fondaparinux in patients with  
unstable angina or non-ST elevation myocardial infarction compared to historical  
controls treated with enoxaparin. 
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REVIEW OF LITERATURE 
 
Each year about 1.3million patients have unstable angina or non-ST elevation myocardial 
infarction, a condition also referred to as non-ST elevation acute coronary syndrome 
(NSTE-ACS). 9  Acute total occlusion of a coronary artery usually causes ST elevation 
myocardial infarction (STEMI), whereas UA/NSTEMI usually results from severe 
obstruction, but not total occlusion of the culprit coronary artery. These potentially life-
threatening disorders are a major cause of emergency medical care and hospitalization in 
developed and developing world.  
 
 
Definition and classification 
 
Unstable angina is defined as angina pectoris or equivalent type of ischemic discomfort 
which occurs at rest or with minimal exertion, with at least one of 3 features 1) usually 
lasting more than 20 minutes, 2) being severe and described as frank pain and of new 
onset (i.e., within 1 month) and 3) occurring with a crescendo pattern (i.e., more severe, 
prolonged, or frequent than previously). 2 Of this group, approximately one half will have 
evidence of myocardial necrosis on the basis of elevated cardiac serum markers, and thus 
have a diagnosis of NSTEMI. 
A clinical classification of UA/NSTEMI by Braunwald has been found to be useful  in risk 
stratification.10  
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Patients fall into 3 groups 
1. primary unstable angina 
2. Secondary angina (angina related to precipitating factors such as anemia) 
3. Post-MI unstable angina 
Patients are also classified according to the severity of the ischemia. 
This classification predicts coronary thrombus at angiography, as well as prognosis. 
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PATHOPHYSIOLOGY 
Five pathophysiological processes may contribute to the development of  UA/NSTEMI. 11  
The acute event usually involves thrombus formation at the site of a ruptured or eroded 
atherosclerotic plaque, is currently referred to as atherothrombosis, a term that that is 
replacing atherosclerosis.  
 
 
 
1. Plaque rupture or erosion with superimposed non-occlusive thrombus – the most 
common cause 
2. Dynamic obstruction – coronary spasm as in Prinzmetal angina  
3. Progressive mechanical obstruction 
4. Inflammation 
5. Secondary unstable angina due to increased demand or decreased supply (anemia). 
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A sequence of events has been documented in UA/NSTEMI, in which there is first a 
reduction in coronary sinus oxygen saturation (signifying a reduction in coronary blood 
flow), then ST segment depression, followed by chest discomfort, and elevation in blood 
pressure or heart rate.15 
 
 
Presentations of UA and NSTEMI 
 
 
Women present more often with unstable angina, comprising 30 to 45% of patients with 
unstable angina compared with 25 to 30% of patients with NSTEMI and 20% of the patients 
with STEMI. In comparison to patients with STEMI, patients with unstable angina have 
higher rates of prior MI, angina, previous coronary revascularization and extra-cardiac 
vascular disease. Indeed, approximately 80% of patients with UA/NSTEMI have a history of 
cardiovascular disease and most have evidence of prior coronary risk facors.16 
 
Angina is graded according to the Canadian Cardiovascular Society classification.12  
Non–ST-elevation MI generally presents as prolonged, more intense rest angina or angina 
equivalent. 
  
The 5 most important factors on the initial history, in order of importance, are  
1) Nature of the anginal symptoms 
2) Prior history of CAD 
3) Sex (male) 
4) Older age 
5) An increasing number of traditional risk factors.13,14 
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In patients without preexisting clinical CAD, older age is the most important factor. 
Patients with UA/NSTEMI may have discomfort typical of chronic angina except that the 
episodes are more severe, are prolonged, occur at rest, or are precipitated by less exertion. 
 
Many people are unaware that symptoms besides chest discomfort, such as shortness of 
breath, diaphoresis, or extreme fatigue, can represent anginal equivalents.18 
The average UA/NSTEMI patient does not seek medical care for approximately 2 hours 
after symptom onset.17 Reasons for this delay have been studied and include a mismatch 
between expectation and actual symptoms and an impression that symptoms are self-
limited or are due to other chronic conditions.19,20 
  
As many as one half of all Acute Myocardial Infarctions (AMI) are clinically silent or 
unrecognized, and one third present with symptoms other than chest discomfort. Patients 
without chest discomfort are more likely to be older, to be women, to have diabetes 
mellitus, to have prior HF, and to delay going to the hospital. They also are less likely to be 
diagnosed correctly initially and to receive appropriate therapies. 21 
  
Clinical examination 
The physical examination may be unremarkable or may support the diagnosis of ischemia. 
Signs that suggest that UA/STEMI involves a large fraction of the LV include diaphoresis, 
pale cool skin, sinus tachycardia, a third or fourth heart sound, lung basilar rales and 
hypotension.1 
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ECG 
In UA/NSTEMI, ST depression or transient ST elevation and T wave changes occur in up to 
50% of patients. ST deviation is a specific and important measure of ischemia and 
prognosis. Traditionally, ST segment depression has only been considered significant if it is 
more than or equal to 0.1mv as occurs in 20 to 25% of patients. An additional 20% of 
patients will present with 0.05 mv  ST depression and they can have an adverse prognosis 
approaching that of patients with 0.1mv ST depression. Transient (<20 min) ST segment 
elevation which occurs in approximately 10% of patients, portends the worst prognosis in 
UA/NSTEMI. T wave changes are sensitive but not specific for acute ischemia, unless they 
are marked (>0.3 mv).1  
 
Early risk stratification 
Patients who present with chest discomfort should undergo early risk stratification for the 
risk of cardiovascular events (e.g., death or [re]myocardial infarction).1 
 
If the initial ECG is not diagnostic but the patient remains symptomatic and there is high 
clinical suspicion for acute coronary syndrome, serial ECGs, initially at 15- to 30-min 
intervals, should be performed to detect the potential for development of ST-segment 
elevation or depression.  
 
Cardiac biomarkers should be measured in all patients who present with chest discomfort 
consistent with acute coronary syndrome. A cardiac-specific troponin is the preferred 
marker. Patients with negative cardiac biomarkers within 6 h of the onset of symptoms 
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consistent with acute coronary syndrome should have biomarkers re-measured in the time 
frame of 8 to 12 h after symptom onset.22  
 
 
Several risk-prediction models exist for patients with acute coronary syndrome, both from 
randomized clinical trials and from registries. 
The Global Registry of Acute Coronary Events (GRACE) prediction model is a robust tool 
for predicting in hospital and 6-month mortality in patients with all types of acute coronary 
syndrome.23  The European Society of Cardiology Guidelines for the diagnosis and 
treatment of patients with acute coronary syndrome recommend the GRACE risk score as 
the preferred classification, and the ACC/AHA Guidelines gives the option of using one of 
three validated risk scores—GRACE, Thrombolysis in Myocardial Infarction (TIMI) or, 
Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin 
Therapy (PURSUIT), in helping to select medical and interventional therapies.24,25 
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Early risk stratification – ACC/AHA recommendations 
Class I 
1. A rapid clinical determination of the likelihood risk of obstructive CAD (i.e., high, 
intermediate, or low) should be made in all patients with chest discomfort or other symptoms 
suggestive of an acute coronary syndrome (ACS) and considered in patient management.  
2. Patients who present with chest discomfort or other ischemic symptoms should undergo  
early risk stratification for the risk of cardiovascular events that focuses on history, physical 
findings, ECG findings, and biomarkers of cardiac injury and results should be considered in 
patient management. 
CLASS IIa  
1. Use of risk-stratification models, such as the Thrombolysis In Myocardial Infarction (TIMI) 
or Global Registry of Acute Coronary Events (GRACE) risk score or the Platelet Glycoprotein 
IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) risk 
model can be useful to assist in decision making with regard to treatment options in patients 
with suspected ACS. 
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 Use of the TIMI risk score for UA/NSTEMI to predict the benefit of an early invasive 
strategy. TIMI risk score was applied in TACTICS-TIMI 18 trial. Seventy five percentage of 
patients had a risk score of 3 or higher, and in these patients a significant benefit of an 
invasive strategy was observed. 26 
 
Rationale for the Conservative Strategy 
 
The conservative strategy seeks to avoid the routine early use of invasive procedures 
unless patients experience refractory or recurrent ischemic symptoms or develop 
hemodynamic instability. With this strategy, an early echocardiogram should be  
considered to identify significant LV systolic dysfunction. 
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In addition, an exercise or pharmacological stress test is recommended before or shortly 
after discharge to identify patients with latent ischemia who could benefit from 
revascularization. The use of aggressive anticoagulant and antiplatelet agents has reduced 
the incidence of adverse outcomes in patients managed conservatively (ACC/AHA).1 
 
  
Rationale for the Invasive Strategy 
 
The routine use of angiography within 24 h of hospital admission provides an invasive 
approach to risk stratification. It can identify the 10% to 20% of patients with no significant 
coronary stenosis as well as the approximately 20% with 3-vessel disease with LV 
dysfunction or left main CAD who derive a substantial survival benefit from CABG. For the 
other approximately 60% to 70%, PCI of the culprit lesion can reduce subsequent 
hospitalizations and the need for multiple antianginal drugs. Contemporary anticoagulant 
and antiplatelet therapies have lessened the early hazard of PCI.  
Excluding those in need of urgent intervention, 2 alternatives for the invasive approach 
have emerged: early (“immediate”) or deferred angiography (i.e., before or after a 12- to 48-
hours window).  
Support for immediate angiography comes from the Intracoronary Stenting with 
Antithrombotic Regimen Cooling-off Study (ISAR-COOL). 27 In that trial patients randomized 
to immediate angiography had fewer deaths or MIs at 30 d (5.9% vs. 11.6%, p= 0.04).  
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Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) trial 
randomized patients to routine invasive or selective invasive management. At the end of 
one year, there was no significant difference in the composite ischemic end point. 28 
 
RITA-3 trial (Third Randomized Intervention Treatment of Angina) randomized patients to 
interventional vs conservative treatment29. At one year, death and MI rates were similar, but 
at 5 years, a significant reduction in death or MI emerged in the early invasive treatment 
arm, mainly in high-risk patients.  
 
Long-term outcomes of the FRagmin and fast revascularization during InStability in 
Coronary artery disease (FRISC II) trial. 30 At 5 years, the invasive strategy was favored for 
the primary end point of death or nonfatal MI (HR 0.81, p = 0.009). Benefit was confined to 
men, nonsmokers, and patients with 2 or more risk factors.  
  
A meta-analysis of 7 randomized trials of management strategies in UA/NSTEMI, supports 
the long-term benefit of an early invasive strategy in terms of all-cause mortality at 2 years, 
nonfatal MI and rate of hospitalization.31 
 
When a patient with high risk ACS is admitted treatment should be initiated and an early 
invasive strategy should be considered.  In an early conservative strategy patients are 
stabilized with medical therapy and angiography and revascularization is performed if 
patients have recurrent symptoms or ischemia, heart failure or serious arrhythmias. 
Patients managed according to early conservative strategy should undergo an assessment 
of LV function and a stress test; they should also undergo angiography if they are found to 
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have ejection fraction less than 40% or if they have an intermediate or high risk exercise 
test result.  
 
 
TREATMENT OF UNSTABLE ANGINA/NSTEMI 
  
Anticoagulants 
 
 
Patients with non–ST-elevation ACS are a heterogeneous population with respect to short- 
and long-term morbidity and mortality. The optimal treatment strategy for these patients 
continues to evolve, and there is a wide range of therapeutic options.  
Anticoagulant therapy is essential to modify the ACS disease process and its adverse 
consequences. A combination of aspirin, an anticoagulant, and additional antiplatelet 
therapy represents the most effective therapy. The intensity of treatment is tailored to 
individual risk. Patients with continuing ischemia or with other high-risk features and should 
undergo early invasive strategy. 
 
UNFRACTIONATED HEPARIN 
 
Anticoagulation traditionally with Unfractionated heparin (UFH) is a cornerstone of therapy 
for patients with UA/NSTEMI. UFH is a heterogeneous mixture of polysaccharide chains of 
molecular weights that range from 5,000 to 30,000 Daltons and that have varying 
anticoagulant activity.32 Unfractionated heparin accelerates the action of circulating 
antithrombin, which inactivates factor IIa (thrombin), factor IXa, and factor Xa. 
Unfractionated heparin prevents thrombus propagation but does not lyse existing thrombi. 
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Meta-analysis of a relatively small, randomized database suggests a reduction of 33% to 
56% (p=0.06 to 0.03) in early ischemic events by the addition of UFH. But reactivation of 
the thrombotic process after the discontinuation of UFH contributes to the loss of early 
gain.33,34 
Unfractionated heparin binds to a number of plasma proteins, blood cells, and endothelial 
cells, leading to the poor bioavailability, especially at low doses, and marked variability in 
anticoagulant response. As a consequence, the anticoagulant effect of heparin requires 
monitoring with the activated partial thromboplastin time (aPTT). The duration of UFH 
therapy in most UA/NSTEMI trials has been 2 to 5 days. The optimal duration of therapy is 
uncertain and likely varies by strategy.  
 
LOW-MOLECULAR-WEIGHT HEPARIN 
 
The low-molecular weight heparins (LMWHs) are obtained through chemical or enzymatic 
depolymerization of the polysaccharide chains of heparin to provide chains with different 
molecular-weight distributions. LMWHs are relatively more potent in inhibiting factor Xa 
than inactivating thrombin.35 
Advantages of LMWH over UFH include decreased binding to plasma proteins and 
endothelial cells and dose-independent clearance, with a longer half-life. This results in 
more predictable and sustained anticoagulation with once- or twice-a-day subcutaneous 
administration that usually does not require laboratory monitoring. In addition to providing 
ease of administration and eliminating the need for monitoring, LMWHs stimulate platelets 
less than UFH and less frequently cause heparin-induced thrombocytopenia.35 
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LMWH (plus aspirin) has proved effective compared with aspirin alone, leading to a 66 
percent reduction in the odds of death or MI.5 Eight randomized trials have directly 
compared a LMWH with UFH. Trials with dalteparin and nadroparin reported similar rates 
of death or nonfatal MI compared with UFH, whereas 5 of 6 trials of enoxaparin favored 
enoxaparin. This benefit of enoxaparin was largely by a reduction in nonfatal MI. 
 
With an early invasive strategy, outcomes with UFH and LMWH (enoxaparin) were 
similar.36 Trials which evaluated the potential benefit of prolonged administration of LMWH 
after hospital discharge, showed little or no benefit beyond the acute phase. 30 LMWH is 
associated with more frequent minor but not major bleeding. A post hoc analysis from the 
SYNERGY trial suggested that some of the excess bleeding seen with enoxaparin could be 
explained by crossover to UFH at the time of PCI.36It thus appears reasonable to maintain 
consistent anticoagulant therapy from the pre-PCI phase throughout the procedure itself. 
 
A prospective analysis of the A to Z trial showed that enoxaparin provided significant 
benefit over UFH in patients managed conservatively but not in those managed 
invasively.37 
 
Two new anticoagulants, fondaparinux and bivalirudin, have undergone favorable testing  
in clinical trials and are recommended as alternatives to unfractionated heparin and low-
molecular-weight heparins for specific or more general applications. 
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FACTOR XA INHIBITORS 
 
Factor Xa inhibitors act proximally in the coagulation cascade to inhibit the multiplier effects 
of the downstream reactions, thereby suppressing thrombin generation.38  
 
FONDAPARINUX 
 
Fondaparinux sodium is the first of a new class of synthetic antithrombotic drugs.  It is the 
sodium salt of a sulphated pentasaccharide, obtained totally by chemical synthesis. 
  
Mechanism of action 
The antithrombotic activity of fondaparinux is the result of antithrombin III (AT III) -mediated 
selective inhibition of factor xa. By selectively binding to AT III, fondaparinux potentiates 
about 300 times the the innate neutralization of factor xa by AT III.39  Neutralization of factor 
Xa interrupts the blood coagulation cascade and thus inhibits thrombin formation and 
thrombus development. 
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Mechanism of action of fondaparinux. Figure (1) The activation of the coagulation cascade 
results in the formation of thrombin and a fibrin clot. The inhibition of Factor Xa by 
antithrombin (ATIII) is very slow. (2) Fondaparinux binds specifically to ATIII. ATIII 
undergoes a conformational change after binding to fondaparinux. Bound to fondaparinux, 
ATIII inhibits Factor Xa selectively and rapidly. By inhibiting Factor Xa, thrombin generation 
and fibrin formation are blocked. (3) Fondaparinux is released to act on other molecules of 
ATIII.  
Fondaparinux also inhibits clot-bound Factor Xa, but not Factor Xa within the 
prothrombinase complex.  When released from ATIII, fondaparinux can exert its action 
again; each molecule of fondaparinux mediates the inhibition of several molecules of Factor 
Xa. The highest therapeutic doses of fondaparinux (which result in fondaparinux plasma 
concentrations up to 1.2 μm at 10 mg once daily) do not saturate plasma ATIII, the plasma 
concentration of which is 2–3 μm. By increasing the ability of ATIII to inhibit Factor Xa, a 
factor situated at the junction of the intrinsic and extrinsic pathways of the coagulation 
cascade, fondaparinux efficiently inhibits thrombin generation. Its synthetic nature 
eliminates the theoretical risk of pathogen contamination and assures batch-to-batch 
consistency. 39  
 
PHARMACODYNAMICS 
 
The effect of therapeutic doses of fondaparinux on routine laboratory hemostasis tests, 
including activated partial thromboplastin time, prothrombin time, activated clotting 
time and bleeding time, is very limited.40,41 When necessary, fondaparinux may be 
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assayed in plasma using a specific anti-Factor-Xa chromogenic method. 42 
Fondaparinux did not exhibit cross-reactivity with heparin-induced thrombocytopenia (HIT) 
sera, did not bind to platelet factor4, did not influence lipid metabolism and did not alter 
central nervous system, cardiovascular, respiratory, renal or gastrointestinal function. 
 
Preclinical data reveal no special risk for human based on conventional studies of safety 
pharmacology, repeated dose toxicity (up to 3 months) and genotoxicity (in vitro and in 
vivo). 39 
 
 
  
Pharmacokinetics 
 
 
Fondaparinux administered by subcutaneous injection is rapidly and completely absorbed. 
In contrast to the heparins, fondaparinux selectively binds to antithrombin and causes rapid 
and predictable inhibition of factor Xa.38. Fondaparinux has a bioavailability via 
subcutaneous injection of 100% and reaches half maximum plasma concentration within 25 
minutes with a half-life of 15 hours.  
It has linear pharmacokinetics and low inter- and intra-individual variability, thus obviating 
the need for laboratory monitoring and enabling a once-daily dosing scheme. After once 
daily dosing, steady state of plasma levels is obtained after 3 to 4 days. Distribution volume 
is limited and consistent with blood volume. Fondaparinux is highly and specifically bound 
to AT III in plasma. There is no evidence of biotransformation.  
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Fondaparinux is renally cleared and reduced plasma clearance is observed in patients with 
renal insufficiency. It is eliminated in urine mainly as unchanged drug. The elimination half-
life is 17-21 hrs in healthy subjects. 43 
 
Fondaparinux does not inhibit cytochrome p450 isoenzymes. In clinical studies performed 
with fondaparinux, the concomitant use of oral anticoagulants, antiplatelets, non-steroidal 
anti-inflammatory drugs, and digoxin did not affect the pharmacokinetics of fondaparinux.41 
In addition, fondaparinux neither influenced the pharmacodynamics of warfarin, acetyl 
salicylic acid and digoxin, nor the pharmacokinetics of digoxin at steady state. 
  
At high doses used in safety studies, adequate exposure was confirmed. This exposure 
increase with dose, but with evidence of non-linear pharmacokinetics due to saturable 
protein binding (AT III).The factor Xa inhibitors do not have any action against thrombin that 
is already formed, a possible explanation for the increased rate of catheter associated 
thrombosis with fondaparinux. 43 
  
Advantages of the pentasaccharide factor Xa inhibitor fondaparinux over UFH include 
decreased binding to plasma proteins and endothelial cells and dose-independent  
clearance with a longer half-life, which results in more predictable and sustained 
anticoagulation and allows fixed-dose, once-daily subcutaneous administration.  
As with the LMWHs, fondaparinux does not require laboratory monitoring.  
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It is available in the form of disposable pre-filled syringes. The solution is sterile,  
endotoxin free, isotonic and suitable for IV or subcutaneous injection. 
 
 
Clinical trials with fondaparinux 
 
Studies in healthy volunteers 
Safety and pharmacokinetics of fondaparinux was assessed in 21 phase I studies in 
healthy male and female, young and elderly subjects. Moreover a study was performed in 
patients with renal impairment.  
32 
 
Pharmacodynamic data in human with fondaparinux are in agreement with a selective 
inhibition of factor Xa.  No significant changes have been observed for the primary 
hemostasis parameters. According to a study in healthy volunteers, recombinant factor VIIa 
is capable of normalizing coagulation times and thrombin generation during fondaparinux 
treatment.  Recombinant factor VIIa may be useful to reverse the anticoagulant effect of 
fondaparinux in case of serious bleeding complications or need for emergency surgery 
during treatment with fondaparinux. 43 
 
Study in patients 
 
Prevention of  venous thromboembolism  
A study evaluated the response of fondaparinux in prevention of venous thromboembolism 
in patients undergoing major orthopaedic surgery. 
Four phase III studies to demonstrate the superior efficacy of fondaparinux 2.5 mg once 
daily SC over enoxaparin in preventing venous thromboembolism – Ephesus study, 
Pentathalon, Pentamarks and Penthifra.44 Evaluation of pooled data revealed an overall 
odds reduction of 56% for efficacy compared to enoxaparin. Hence the overall result 
demonstrated fondaparinux to be superior to enoxaparin for efficacy. Overall major and 
minor bleeding rates were similar between fondaparinux 2.5mg and LMWH. 
 
Prevention of  venous thromboembolism in high risk abdominal surgery 
A phase III study named Pegasus to compare the efficacy and safety of fondaparinux 
2.5mg given post-operatively with dalteparin concluded that post-operative administration 
of fondaparinux was at least as effective as safe as dalteparin in patients at high risk for 
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venous thromboembolism, with a significantly superior control achieved in patients with 
cancer surgery receiving fondaparinux.45 
 
 
Prevention of venous thromboembolism in acutely ill medical patients  
The Artemis study demonstrated that fondaparinux is safe and effective in prevention of 
venous thromboembolism in acutely ill medical patients at moderate to high risk. 46  
 
 
Treatment of venous thromboembolic disease  
Rembrandt study – a multi-centre, randomized, double-blind dose ranging study performed 
in patients with symptomatic proximal deep vein thrombosis (DVT). Fondaparinux was 
compared with dalteparin. Fondaparinux appears to be an effective and safe treatment for 
patients with DVT across a wide range of doses (5.0, 7.5, 10.0 mg OD SC).47  
The MATISSE- DVT study and MATISSE- PE study showed that once daily subcutaneous 
fondaparinux was at least as effective and equally safe as the reference therapy (bid body 
weight-adjusted enoxaprin in DVT and aptt adjusted UFH in pulmonary embolism) in the 
initial treatment of symptomatic venous thromboembolism. 48,49  
Thus it is proved that Fondaparinux is more effective than enoxaparin in preventing venous 
thrombosis in patients undergoing orthopedic surgery and is similar in effectiveness to 
enoxaparin or UFH in patients with deep-vein thrombosis or pulmonary embolism. 
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FONDAPARINUX IN ACUTE CORONARY SYNDROME 
In the PENTALYSE dose ranging study, it was hypothesized that prolonged factor Xa 
inhibition with fondaparinux may be an effective and safe antithrombotic co-therapy to 
thrombolysis in acute myocardial infarction. 50 Patients with STEMI were treated with 
alteplase and randomized to UHF, given intravenous (IV) for up to 72hrs or to 
fondaparinux.  Fondaparinux was given in 3 different doses – 4mg, 8mg, and 12mg, 
administered daily for 5 to 7 days, IV on the first day, then subcutaneously. TIMI grade 3 
flow rates at 90 min were similar in all groups.  Moreover, a strong trend towards less re-
occlusion of the infarct-related vessel at day 5 to 7 was observed with fondaparinux. Also 
fewer revascularization during the 30-day follow-up period were performed in patients given 
fondaparinux. The primary safety endpoint, the combined incidence of intracranial 
haemorrhage and need for blood transfusion, was identical for fondaparinux and UFH.  
 
A dose ranging PENTUA study in patients with UA/ NSTEMI was performed testing four 
fondaparinux dose levels (2.5, 4.0, 8.0 and 12.0). 51 This was a double blind, randomized 
controlled study testing four fondaparinux doses and a body weight adjusted dose regimen 
of enoxaparin (1 mg/kg bid). The objectives were to assess the dose response relationship 
of fondaparinux for the primary efficacy endpoint - the composite of death, AMI, recurrent 
ischemia and to select the optimum dose levels for treating patients with non-ST elevation 
ACS.  All fondaparinux dose levels tested appeared to be efficacious and at least as 
effective as enoxaparin (1 mg/kg bid). With respect to safety, all doses of fondaparinux 
appeared to be as safe as enoxaparin and also no dose-related safety profile was noted. 
However, it was noticed that in the fondaparinux 2.5mg dose group, the incidence of death, 
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MI and recurrent ischemia was significantly lower than in the enoxaparin group and no 
major bleeding was observed. Consequently, the lowest dose of fondaparinux (2.5mg) has 
been selected for further clinical studies in acute coronary syndromes. 
A Pilot trial (ASPIRE) involving patients with acute coronary syndromes undergoing 
percutaneous coronary intervention suggest that fondaparinux may be as effective as 
enoxaparin or safer than unfractionated heparin.52  
There are several reasons why fondaparinux might be used instead of enoxaparin in UA 
and NSTEMI. 62 First, the use of multiple antithrombotic therapies and the performance of 
acute interventions routinely in ACS have led to higher rates of major bleeding. New 
anticoagulants must therefore demonstrate either reduced bleeding complications without 
compromising efficacy or alternatively significantly reduce major efficacy events to a 
clinically important degree that would make any additional bleeding risk acceptable. The 
ideal scenario would be if the new anticoagulant improved efficacy and reduced bleeding.  
In the trials of prevention of venous thrombosis, fondaparinux was clearly associated with 
improved efficacy over enoxaparin, with no significant increase (and in some trials a 
reduction) in major bleeding, particularly when the 2.5-mg dose was used. 
Second, fondaparinux is simpler to administer because it is given once daily versus a twice 
daily enoxaparin regimen.  
Third, fondaparinux is a synthetic compound, and thus there is no chance of animal to 
human transmission of infectious agents. By contrast, enoxaparin is harvested from porcine 
intestines, introducing the potential for animal to human transmission. Although this has not 
been a major concern to date, it remains a theoretical possibility with potentially important  
consequences for treatment of human subjects. 
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Idraparinux 
A synthetic long acting analogue of fondaparinux with a prolonged half-life and 10-fold 
higher binding to factor X that can be given in fixed weekly doses. However, a large trial 
comparing  Idraparinux and vitamin K antagonists for prevention of thromboembolism in 
patients with atrial fibrillation was stopped pre-maturely because of excess bleeding. 53 
 
OASIS-5  
The Organization to Assess Strategies for Ischaemic Syndromes (OASIS)-5 investigators 
evaluated the use of fondaparinux in 20,078 patients with UA/NSTEMI. 8 Patients were 
randomized (double-blind, double-dummy design) to a control strategy of enoxaparin 1.0 
mg/ kg subcutaneous twice daily (reduced to 1.0 mg/ kg once daily for patients with an 
estimated creatinine clearance < 30 ml / min) or to fondaparinux 2.5 mg subcutaneously, 
once daily. Unfractionated heparin initially was not used with PCI, but because of an 
increased incidence of catheter associated thrombus, the protocol was amended to permit 
the use of open-label UFH at the investigator’s discretion. 
 The OASIS-5 primary composite outcome (death, MI, or refractory ischemia at 9 d) was 
similar in the 2 groups (579 with fondaparinux [5.8%] vs. 573 with enoxaparin [5.7%]; 
hazard ratio [HR] 1.01; 95% CI 0.90 to 1.13), which satisfied pre-specified non-inferiority 
criteria. 
 Rates of major bleeding at 9 d were lower with fondaparinux (2.2% vs. 4.1%, p less than 
0.001), which yielded a lower efficacy plus safety composite. This difference persisted 
during long-term follow-up. Fondaparinux was associated with a significant reduction in 
rates of major (hazard ratio, 0.55; 95 % confidence interval, 0.41 to 0.74; P<0.001) as well 
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as minor bleeding (1.1% in the fondaparinux group vs. 3.2% in the enoxaparin group. 
Fondaparinux significantly reduced the rate of death, as well as the rate of the composite of 
death, myocardial infarction, and stroke at 30 days. Fondaparinux was associated with 
substantially less bleeding — an effect that translated into lower long-term mortality and 
morbidity. 
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 Primary composite events trended lower in the fondaparinux group at 30 d and 6 months; 
6-month rates of death (5.8% vs. 6.5%) and death, MI, and stroke (11.3% vs. 12.5%) were 
also lower at 6 months with fondaparinux. 
  
Three important findings of the OASIS 5 trial 
1)Iin the short term, fondaparinux and enoxaparin have similar efficacy.  
2) As compared with enoxaparin, fondaparinux substantially reduces bleeding.  
3) The reduced bleeding that accompanies the use of fondaparinux is associated with lower 
long-term mortality and morbidity. 
 
Although the rate of death and MI and severe bleeds did not differ significantly between the 
two groups in patients undergoing PCI, there was a higher rate of guiding catheter 
thrombosis and more coronary complications (new angiographic thrombus, catheter 
thrombus or no reflow) with fondaparinux. But addition of UFH with fondaparinux during 
PCI largely avoided these complications. Given the very limited time for antithrombotic 
therapy prior to the procedure and the need for UFH during the procedure, there is 
probably little advantage in using fondaparinux as the initial treatment in patients in whom 
primary PCI is intended. In all other patients initial management with fondaparinux followed 
by standard UFH during PCI is an attractive choice. 
Fondaparinux appears to represent a preferred anticoagulant strategy in those at higher 
risk of bleeding managed with a noninvasive strategy. 
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Noting that fondaparinux can be used as a single fixed dose - the simplicity of the regimen, 
lack of monitoring, and its safety and efficacy in the full spectrum of acute coronary 
syndrome facilitates the use of fondaparinux in a range of settings. It may even be 
applicable in the pre-hospital or post-hospital settings in appropriate patients. The use of 
aggressive anticoagulant and antiplatelet agents has reduced the incidence of adverse 
outcomes in patients managed conservatively. 
 
Clinical trials data continue to build support for an initial invasive strategy for higher-risk 
UA/NSTEMI patients (as assessed by troponin positivity or a formal risk score); in contrast, 
such a strategy is not of benefit in low-risk patients especially women, in whom an initially 
conservative strategy is recommended.31 
 fondaparinux will be more preferred in settings in which the use of angiographic-based 
reperfusion is not routine. 
 
OASIS 6 
  
OASIS-6 trial evaluated the impact of fondaparinux compared with standard approaches to 
antithrombotic therapy in a broad range of patients with STEMI in preventing the primary 
and composite outcome of death or reinfarction at 30 days.54 The trial demonstrated a 
moderate reduction in mortality and reinfarction with the use of fondaparinux compared with 
usual care and this benefit persists long term. There was a higher rate of guiding catheter 
thrombosis if PCI is performed without UFH, but this is largely avoided if UFH is used 
before the procedure.  
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Although the use of UFH for PCI in fondaparinux-treated patients appears to be safe and 
effective, a limitation is that the number of patients treated with this approach remains 
relatively modest.  
 
The net clinical benefit of fondaparinux was observed consistently in those undergoing both 
an early invasive and a delayed invasive management strategy and was due primarily to a 
reduction in major bleeding. These benefits were even more marked after the exclusion of 
patients referred for primary PCI for STEMI, for whom data from the OASIS 6 trial 
demonstrated no tangible benefit of fondaparinux over heparin.54,61 For all other patients 
receiving an invasive strategy, it appears that fondaparinux is at least as good an option, if 
not a better one, than either unfractionated or low-molecularweight heparin. These data 
support the recent American College of Cardiology/American Heart Association and 
European Society of Cardiology guidelines for management of unstable angina and non-
STEMI, in which fondaparinux is cited as a class I recommendation for either an invasive or 
a conservative management strategy.1 
 
Importantly, the net clinical outcome was consistent with fondaparinux regardless of 
whether it was coadministered with other effective antithrombotic drugs (including 
thienopyridines and glycoprotein IIb/IIIa antagonists) and other therapies such as statins 
and blockers of the rennin-angiotensin system. Among patients undergoing PCI for ACS 
without ST-segment elevation and rescue, routine, or facilitated PCI for STEMI, 
fondaparinux reduced bleeding with similar rates of death, MI, or stroke compared with 
heparin.54 The small absolute excess in catheter thrombus when fondaparinux was used as 
the sole anticoagulant (7 per 1000 patients) did not seem to translate into an increase in 
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clinical ischemic events between groups. This finding suggests that the reduction in 
bleeding with fondaparinux may have offset any increase in the risk of major events related 
to catheter thrombus. Furthermore, the risk of catheter thrombus was essentially eliminated 
when adjunctive UFH was administered in the catheterization laboratory immediately 
before the PCI procedure. At present, on the basis of limited experience in OASIS-5 and 
concerns raised by OASIS-6, UFH (50 to 60 U per kg IV) is recommended with a 
fondaparinux strategy during angiography/PCI.1  
 
Future trials are therefore needed to identify the optimal dose of UFH to be used in 
fondaparinux treated patients. The Fondaparinux Trial With UFH During Revascularization 
in Acute Coronary Syndromes (FUTURA) OASIS 8 trial will randomize 2000 fondaparinux-
treated ACS patients undergoing PCI to receive 2 doses of UFH (standard, activated 
clotting time guideline–recommended doses versus empirical low-dose UFH).55  
 
Aggressive antiplatelet and anticoagulant therapies combined with an invasive strategy 
improve outcomes but also increase the risk of complications, including bleeding.56,57,58  
Bleeding is prognostically important because it is associated with an increased risk of 
mortality as well as recurrent ischemic events. 59,63  
 
This highlights the importance of having antithrombotic treatments that are safe, easy to 
administer, less expensive, and that can be given to a broad range of patients with ACS. 
As patients at very high or very low risk are usually excluded from clinical trials, it is 
critically important to determine whether new treatments show evidence of benefit across 
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the risk spectrum and whether there is net clinical benefit at all levels of risk when efficacy 
is balanced against bleeding.60 
 
 
ACC/AHA 2007 Guidelines for the Management of Patients with Unstable 
Angina/Non-ST-Elevation Myocardial Infarction 1 
 
 
ANTICOAGULANT THERAPY 
 
CLASS I 
 
Anticoagulant therapy should be added to antiplatelet therapy in UA/NSTEMI patients as 
soon as possible after presentation. 
a. For patients in whom an invasive strategy is selected, regimens with established efficacy 
at a Level of Evidence: A include enoxaparin and UFH, and those with established efficacy 
at a Level of Evidence: B include bivalirudin and fondaparinux. 
b. For patients in whom a conservative strategy is selected, regimens using either 
enoxaparin or UFH (Level of Evidence: A) or fondaparinux (Level of Evidence: B) have 
established efficacy. 
c. In patients in whom a conservative strategy is selected and who have an increased risk 
of bleeding, fondaparinux is preferable. (Level of Evidence: B) 
CLASS IIa 
For UA/NSTEMI patients in whom an initial conservative strategy is selected, enoxaparin or 
fondaparinux is preferable to UFH as anticoagulant therapy, unless CABG is planned within 
24 h. (Level of Evidence: B)  
It is suggested by ACC/AHA 2007 guidelines that each institution agree on an approved 
anticoagulant approach most consistent with local practice and preference. 
45 
 
 Relevance of the present study 
 
We conducted a preliminary study among our patients presented with UA/NSTEMI and who 
received enoxaparin, to find out the incidence of the primary outcome (the composite of 
death, myocardial infarction ad refractory ischemia at 1 month) and individual components 
of this composite. 
The outcomes for this retrospective cohort of our patients who received enoxaparin were 
considerably less favorable  than that obtained for enoxaparin recipients in the OASIS 5 
trial, in spite of similarities in indications for use of enoxaparin. It would be prudent to 
conduct a systematic prospective evaluation of patients treated with fondaparinux to 
evaluate whether there are any differences in their outcomes compared to patients given 
enoxaprin in our retrospective cohort.  
Fondaparinux is given once daily while enoxaparin is given twice daily. The costs of  
treatment between the two, for all brands of both drugs, favor fondaparinux. 
This study is designed to assess the utility of fondaparinux in our current clinical  
practice. 
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METHODS 
                                                        
This is a prospective study to test the hypotheses that in the acute treatment of patients 
with unstable angina/ myocardial infarction without ST elevation, fondaparinux is safe and 
effective in preventing death, myocardial infarction or refractory ischemia.   
The study was performed among patients from the cardiology department of Christian 
Medical College, Vellore; a tertiary care institute in South India. 
The study protocol was approved by the institutional review board (IRB) and the ethics 
committee. 
 
 
Study Patients 
Patients who consent to participate in this trial were assigned to the study group within 48 
hours after the onset of symptoms to receive fondaparinux at a dose of 2.5mg once daily 
subcutaneously, for a minimum duration of 5 days. With recurrence of angina within 5 days 
of treatment fondaparinux was continued and the need for early revascularization was  
re-emphasized. PCI could be done at any time and fondaparinux was stopped following 
PCI. Patients received other standard treatments as is clinically indicated.  An early 
invasive strategy is offered to high risk patients and those who develop recurrent angina or 
 re-infarction in spite of adequate medical management. In patients who received 
fondaparinux, 50 to 60 U per kg IV bolus of UFH is given during PCI. 
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Comparator:  A preliminary study was conducted to find out the incidence of the 
composite outcomes and individual components of this composite, with enoxaparin.  
Consecutive inpatient and outpatient medical records of 44 patients who presented  
to the chest pain unit with unstable angina/NSTEMI who were given enoxaparin were  
analyzed.  
The results of the record review are as follows:  [1] The composite outcome of death,  
Non-fatal MI and refractory angina at 1 month was 34% (vs 8.6% in enoxaparin arm  
of OASIS-5). The individual outcomes a) death – 6.8% (vs 3.5% in OASIS) 
 b) refractory  ischemia – 27.2% (vs 2.2% in OASIS). [2] The rate of revascularization 
 procedures was much lower in our population – (PCI/CABG at 30 day)- 27.2% 
(vs 54.2% in OASIS).  [3] There were no documented major bleeding or stroke in 
 30 days period, among our patients. Thus, it is apparent that the outcomes in 
 our patient population treated with enoxaparin differed from the patients given  
enoxaparin in the landmark (OASIS) trial, in many aspects in that patients in the  
enoxaparin arm in OASIS had better clinical outcome and more frequent  
revascularization procedures.  
 
Historical controls were given enoxaparin 1 mg/kg twice daily [44 patients treated with 
enoxaparin].  In patients whose creatinine clearance was below 30 ml per minute, the 
enoxaparin dosage was reduced to 1 mg per kilogram once daily. Enoxaparin was given  
for two to eight days or until the patient was clinically stable, in an approach consistent  
with the current approval for its use in persons with unstable angina and myocardial 
infarction without ST elevation. All patients received other standard treatments.  
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Key inclusion /Exclusion Criteria 
 
Inclusion Criteria:  
Unstable angina as defined as angina pectoris or equivalent type of ischemic discomfort 
with at least one of 3 features:  
a) Occurring at rest or with minimal exertion and usually lasting more than 20 min.  
b) Being severe and frank pain and of new onset  
c) Occurring with a crescendo pattern  
Patients were assigned to study group within 48 hours after the onset of symptoms and 
were eligible if they met at least one of the two following criteria: 1) an elevated level of 
troponin or creatine kinase MB, 2) ECG changes indicative of ischemia. (ie, ST depression 
at least 1mm in 2 contiguous leads or T-wave inversion >3 mm or any dynamic ST shift or 
transient ST elevation) 
 
Exclusion Criteria:  
1. Contraindications to anticoagulation  
2. Recent hemorrhagic stroke  
3. Indications for anticoagulation other than an acute coronary syndrome  
4.  Serum creatinine level >3 mg/dl.  
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5.  Severe hepatic failure  
6.  Any active major bleeding. 
 
OUTCOMES 
 
Primary outcomes: 
A) Primary efficacy outcome: A composite outcome measure comprising of death/ nonfatal 
myocardial infarction/ refractory angina at 1 month 
B) Primary safety outcome: major bleeding or stroke at 1 month 
 Secondary Outcomes: 
Death, nonfatal myocardial infarction, refractory angina, stroke or major or minor bleeding 
at 1week and rate of revascularization within 1month. 
 
Criteria for diagnosis of acute myocardial infarction 
 
Detection of rise and/ or fall of cardiac biomarker (troponin) together with evidence of 
myocardial ischemia with at least one of the following: 
1) Symptoms of ischemia 
2) ECG changes indicative of ischemia ( new ST-T changes or new LBBB) 
3) Development of pathological Q waves in ECG 
4) Imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality 
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When recurrent myocardial infarction was suspected from clinical signs or symptoms 
following the initial infarction, an immediate measurement of troponin was done. A second 
sample was obtained 3–6 h later. Recurrent infarction was diagnosed if there is a more 
than or equal to 20% increase of the value in the second sample.  
PCI related MI was diagnosed with an increase of biomarkers > 3x99th percentile of upper 
reference limit (URL). 
CABG related MI was diagnosed with an increase of troponin >5x99th percentile of URL 
plus either new Q waves or new LBBB or imaging evidence of new loss of viable 
myocardium. 
  
Refractory ischemia is defined as recurrent ischemic symptoms lasting more than 5 
minutes while on optimal medical therapy with ECG changes indicative of ischemia and 
requiring an additional intervention within 48 hours (revascularization procedure). 
 Classification of  
Classification of hemorrhagic events: 
 
  
TIMI major bleeding involves a hemoglobin drop >5 g/dL (with or without an identified site) 
or intracranial hemorrhage or cardiac tamponade.  
TIMI minor bleeding involves a hemoglobin drop >3 g/dL but ≤5 g/dL, (with or without an 
identified site) or spontaneous gross hematuria, hemoptysis, or hematemesis. 
 
Patients were followed up for 30 days. 
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Statistical Analysis 
Target sample size calculation and rationale: 
  
The sample size was calculated using the rates of clinical endpoints of treatment with 
enoxaparin from the historical data and the expected reduction in the incidence of events 
by using the drug fondaparinux. The study is sufficiently powered for to demonstrate 
superirority of fondaparinux for the primary outcomes.   
Calculation of sample size - formula used: n = (Z alfa+Z beta)2x2pq/(p1-p2)2,  
p1 = 34%(primary endpoint in the historical control), p2 = 8.0% (primary endpoint in the 
landmark trial), p = p1+p2/2 , q =100-p.   n = 40 in each arm.  
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RESULTS 
A total of 40 patients were studied.  
Table 1 shows the baseline characteristics of the patients 
The mean age of the patients was 63.4 +/- 9.3 years; they were predominantly male (73%).  
Majority were diabetic patients 31(77.5%) and 15 (37.5%) patients had suffered a previous 
ST elevation myocardial infarction. 
Mean duration of symptoms before presentation to hospital was 7 hours with a minimum of 
2 hours and maximum of 42 hours.   
The mean duration of treatment was not similar in the 2 groups (5 days in fondaparinux 
group and 3 days in the enoxaparin group. The minimum duration of treatment with 
fondaparinux was 2 days and a maximum of 8 days. Extended duration of antithrombotic 
therapy was given to patients who developed refractory ischemia. 
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Table 1 Patient characteristics 
Variable Number (%) 
Age (yrs) 63.4 +/- 9.3 
Male 29(73%) 
Diabetes mellitus 31(77.5%) 
Previous MI 15(37.5%) 
Previous PCI/CABG 4(10%) 
Mean duration of symptoms (hrs) 7  
Unstable angina 20(50%) 
NSTEMI 20(50%) 
Any ECG abnormality 37(92.4%) 
Patients with GFR<60 ml/min 7(17.5%) 
LV systolic dysfunction 26(65%) 
 
 
An early risk stratification using Thrombolysis In Myocardial Infarction (TIMI) risk-
stratification model was done for all patients included in the study. Thirty one patients 
(77.5%) had a risk score of three or higher and these patients were offered an early 
invasive strategy. But only 2 patients (5%) had undergone PCI during the index 
hospitalization.  
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Table 2 TIMI risk scoring 
Variable Number (%) 
TIMI low risk  9(22.5%) 
TIMI intermediate risk 20(50%) 
TIMI high risk 11(27.5%) 
 
 
Primary outcomes 
The primary efficacy outcome (the composite of death, myocardial infarction, or refractory 
ischemia at 30 days) occurred in 11 (27.5%) of the 40 patients who received fondaparinux 
as compared with 15 (34%) of the 44 patients in the retrospective cohort who received 
enoxaparin. The difference in rate of the primary efficacy outcome observed in this study 
was not statistically significant (p= 0.51). This difference was primarily due to a non-
significant reduction in mortality and refractory ischemia with fondaparinux. 
  
The rates of individual outcomes at 30 days (death or refractory ischemia) in 2 groups  
were analyzed. The difference in the rates of death (5.0 percent in the fondaparinux group 
and 6.8 percent in the enoxaparin group P = 0.72) or the refractory ischemia (22.5% in the 
fondaparinux group and 27.2% in the enoxaparin group; p = 0.61) at 30 days was not 
statistically significant. There was no documented myocardial infarction in either group 
during the 1 month follow up period. 
 
 
55 
 
Figure 1 Primary outcome at 30 days (p=0.51) 
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Figure 2 Death at 30 
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Figure3. Refractory ischemia at 30 days 
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Primary safety outcome 
In our study there was no documented stroke or major bleeding either in patients received 
fondaparinux or in those received enoxaparin. 
 
Outcomes at 1 week 
The rate of composite clinical outcome at 1 week was not significantly different between the 
2 groups (15% in the fondaparinux group and 18% in the enoxaparin group). There was a 
non-significant trend toward a lower rate of death at one week in the fondaparinux group. 
There were no deaths in week in fondaparinux group, but 3 patients died in the enoxaparin 
group at 1 week. This difference mortality was not statistically significant (p= 0.09). Totally 2 
patients died in the fondaparinux group, both between 20th and 30th day. 
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Revascularization procedures 
The rate of revascularization procedures (PCI/ CABG) at 1 month was almost similar in the 
2 groups (22.5% in the fondaparinux group and 27.2% in the enoxaparin group). There 
were no procedure related complications either in patients who underwent PCI during the 
index hospitalization or those who had PCI within 1 month. Heparin was given during PCI 
for patients who received fondaparinux.  
 Table 3 Efficacy outcomes 
 
Time and outcome 
Fondaparinux 
(N = 40) 
Enoxaparin 
(N = 44) 
P value 
 Number (%) Number (%)  
1 week    
Composite (death,MI,RI) 6 (15%) 8 (18%) 0.69 
Death Nil 3 (6.8%) 0.09 
MI Nil Nil  
Refractory ischemia 6 (15%) 5 (11.4%) 0.71 
1 month    
Composite (death,MI,RI) 11 (27.5%) 15 (34%) 0.51 
Death 2 (5%) 3 (6.8%) 0.72 
MI Nil Nil  
Refractory ischemia 9 (22.5%) 12 (27.2%) 0.61 
1 month PCI/CABG 9 (22.5%) 12 (27.2%) 0.61 
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Subgroup analysis 
As expected the rate of primary efficacy outcome was higher in TIMI high and intermediate 
risk groups than the low risk group (composite outcome occurred in 11.1% of patients in 
TIMI low risk group, 25% of patients in intermediate risk group and 45.5% of patients 
 in the high risk group). 
 Figure4. Primary outcome in TIMI subgroups 
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LV systolic dysfunction 
Out of 40 patients 26 (65%) had LV systolic dysfunction by echocardiogram (ECHO).  
The primary composite outcome occurred in 9 out of 26 patients with LV systolic 
dysfunction (34.6%) while only 2 out of 14 patients without LV systolic dysfunction 
 had the outcome (14.3%).  
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Renal failure 
GFR was calculated using the modified MDRD formula. Seven out of 40 patients in the 
fondaparinux group had GFR less than 60ml/min. The rate of primary composite outcome 
at one month was significantly higher in patients with renal failure than in patients with 
normal renal function (57% versus 21.2%, p=0.05). 
 
Medications at discharge and at 1 month 
The mean duration of hospital stay was two days. At discharge all patients were  
on double antiplatelets and a statin. More than 90% of the patients were on  
betablocker and ACE inhibitor/ARB at discharge. At one month only 70% of the  
patients were on regular medications as advised at the time of discharge or at  
1 week follow up. Rest of the patients stopped taking all drugs at the time of  
review after one month.  
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DISCUSSION 
In this study we have evaluated the utility of fondaparinux in management of patients with 
unstable angina/ NSTEMI, in our current clinical practice.   
The effect of fondaparinux versus enoxaparin on the primary composite outcome of death, 
myocardial infarction, and refractory ischemia at 30 days was similar (27.5% versus 34% 
p=0.51) and the differences in rates of death and refractory ischemia at 30 days between 
the 2 groups were also statistically not significant. 
Surprisingly, there were no documented bleeding or stroke in either fondaparinux or 
enoxaparin group during the study period.  
 
The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial 
demonstrated that fondaparinux was non-inferior to enoxaparin while reducing the risk of 
bleeding by 50%.8 Bleeding increased the long term risk of death. In addition, there were 
significantly fewer strokes with fondaparinux than with enoxaparin. Therefore, the OASIS 5 
trial showed a net clinical benefit clearly in favor of fondaparinux.  
Several previous studies have found increased rates of death, stroke, and myocardial 
infarction among persons who had a bleeding episode.59,63 
 
There was no documented bleeding in our patient population. Though the rate of primary 
composite outcome was higher in patients with renal failure than in patients with normal 
renal function, there was no bleeding in this group of patients with increased bleeding risk. 
Similarly there was no bleeding in elderly patients (10 patients in the fondaparinux group 
were 70 years or above). 
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 The absence of major bleeding and stoke in our study population could be due to small 
number of patients and that could also explain the reason for the lack of benefit of 
fondaparinux over enoxaparin. In the OASIS 5 trial, the difference in bleeding appeared to 
account for the reduction in the long term risk of death with fondaparinux. Therefore a 
larger study is needed to prove the benefits of fondaparinux in our patient population.  In 
patients undergoing PCI, the contemporary practice of using double antiplatelets, loading 
dose of clopidogrel and glycoprotein IIb/IIIa inhibitors might lead to more bleeding 
complications. Less number of coronary interventions in our study could be another reason 
for lack of bleeding.  
 
By comparing our study results with landmark trial (OASIS 5) we found that the rate 
 of composite of death, myocardial infarction or refractory ischemia at 1 month, in 
 our study was substantially higher than those rates in the OASIS 5 trial (27.5%  
versus 8.0%, p= <0.001). Similarly the rate of refractory ischemia was significantly 
higher in our population (22.5% versus 2.2%,p=<0.001). But the difference in the 
rate of death at month was not statistically significant. 
   
The higher rate of outcomes in our study was primarily due to a higher rate of  
refractory ischemia. This difference in the outcomes was observed, in spite of  
similarities in indications for use of the anticoagulant therapy.  While analyzing  
the outcomes of our retrospective cohort we found similar results . 
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Similarly the rate of revascularization procedures at 1 month was significantly less 
in our patient population compared to OASIS population (22.5% versus 54.2%,  
p= <0.001).  
In spite of clear indications for immediate coronary angiogram and revascularization, 
in many of our high risk patients,  early PCI was done only in a small number of  
patients.In (TACTICS) TIMI 18 trial, the TIMI risk score was used to assess the 
benefit of an early invasive strategy.26  A significant benefit with invasive strategy  
was observed in patients with a risk score of 3 or higher. Thirty one (77.5%) patients 
 in our study had a TIMI risk score of 3 or higher. Out of these 31 patients only 
 2 patients underwent early PCI.  This could be an important explanation for  
higher rate of refractory angina seen in our study.  
 
When compared to OASIS 5, though there were significantly higher rates of refractory 
angina in our study, the rates of death or MI were not significantly different. In spite of more 
frequent revascularization procedures in OASIS 5, there was no significant reduction in 
major irreversible cardiovascular events (death/ MI) when 2 studies are compared. Thus 
the patients treated with a more aggressive approach were at lower risk of refractory 
angina or readmission for unstable angina.  
At the time of discharge almost all of the patients were on double antiplatelets, 
 betablocker, ACE inhibitor/ ARB and a statin but only 70% of the patients 
continued all medications till the end of 1 month .  About 30% of the patients  
were not on appropriate cardiac medications at 1 month. This poor patient 
 compliance in our population is one of the most important factors leading to  
more frequent complications.  
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When we analyzed the rate of composite outcomes in patients those who were not  
on regular medications, showed a higher rate than those who were on regular medications  
(41.7% in patients who stopped medications and 21.4% in patients who were on  
regular medications). But this difference in the rate was not statistically significant (p=0.19).  
We acknowledge that the sample may be underpowered to detect significant differences  
in subgroup analyses but will provide indicative data. 
 
Thus, it is apparent that the outcomes in our patient population treated with either  
fondaparinux or enoxaparin differed from the patients in the landmark (OASIS) trial,  
 in that patients  in the OASIS trial had better  clinical outcome  and more frequent 
revascularization procedures. 
  
The poorer clinical outcome in our population could be due to  
1) Late presentation and early discharge from the hospital 
2) Non-adherence to medications  
3) Less frequent revascularization procedures (early PCI/CABG) even when indicated  
4) Lack of regular follow up  
The basic reasons for the above mentioned observations are financial constraints and  
lack of awareness among our patients. 
 
Advantages of fondaparinux over enoxaparin 
For management of patients with unstable angina/NSTEMI, fondaparinux have established  
efficacy. Fondaparinux with single daily dosage, promises better patient compliance  
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especially when it has to be continued even after discharge from the hospital.   
Being once daily dosage the cost of treatment with fondaparinux much less than 
 that of enoxaparin. Therefore, fondaparinux is an effective, less expensive,  
and safe antithrombotic agent for treatment of patients with UA/NSTEMI. 
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LIMITATIONS 
1) The number of patients studied was limited and the duration of follow up was 
 short. The findings need to be confirmed in a larger population of patients for a 
 longer period of time.  
2) As the control was retrospective cohort, the present study was limited by lack  
of randomization, incomplete data of the retrospective group, and the differences  
in the baseline patient characteristics between the two groups. 
These limitations should be considered in the interpretation of its results. 
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SUMMARY OF MAIN FINDINGS 
 
 
1) The impact of fondaparinux versus enoxaparin in preventing the death, myocardial 
infarction, and refractory ischemia in patients with unstable angina/NSTEMI at 30 days  
was similar. 
2) In our study there was no documented stroke or major bleeding either in patients 
received fondaparinux or in those received enoxaparin probably because of the small 
number of patients and less number of coronary revascularization procedures. The 
absence of bleeding and stroke could explain the lack of benefit of fondaparinux over 
enoxaparin. 
3) There was a non-significant reduction in mortality with fondaparinux, at 1 week.  
4) The outcomes in our patient population treated with either fondaparinux or  
enoxaparin differed from the patients in the landmark (OASIS) trial,  in that patients  
 in our study had more frequent hospitalizations for refractory ischemia. This could  
be explained by less number of  revascularization procedures. 
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                                                        PROFORMA 
 
 
Name:   
 
Age:                              Sex:               
 
Hospital number: 
  
Occupation: 
 
Address: 
 
Phone number: 
 
Presenting complaints: Chest pain –no (0)/yes(1)  
                                     dyspnoea – no(0)/yes(1)/   
                                     other symptoms– no(0)/yes(1) 
Duration of symptom prior to presentation 
 
Two or more than two anginal episodes in prior 24 h – no(0)/ yes(1) 
 
Heart failure symptoms at presentation – no(0)/ yes(1) 
 
Pulmonary edema at presentation ( settled without ventilatory support)- no(0)/ 
yes(1) 
 
Pulmonary edema requiring ventilatory support – no(0)/ yes(1) 
 
Risk factors: 
  
Age >/= 65yrs – no(0)/ yes(1) 
 
Diabetes mellitus – no(0)/ yes(1) 
 
Three or more than three CAD risk factors – no(0)/ yes(1) 
 
Prior CVA – no(0)/ yes(1) 
 
Known CAD (50% stenosis) 
 
Aspirin within prior 1 week 
 
Post MI angina – no(0)/ yes(1) 
  
77 
 
Secondary angina – no(0)/ yes(1) 
 
Previous myocardial infarction – no(0)/ yes(1) 
                                                      Anterior wall MI – no(0)/ yes(1) 
                                                      LV dys – no(0)/ yes(1) 
Prior PCI – no(0)/ yes(1) 
                   Year- 
                   Within 1 month – no(0)/ yes(1) 
                    BMS (1)/ DES (2) 
                    Indication – ACS (1)/ stable angina (2) 
                     
 
Prior CABG – no(0)/ yes(1) 
                     Year 
                      
Prior history of stable angina : no(0)/ yes(1) 
 
Physical findings ( at presentation): 
Pulse: 
 
BP: 
 
Cardiogenic shock during hospital stay – no(0)/ yes(1) 
 
Cardiac arrest – resuscitated (during hospital stay) – no(0)/ yes(1) 
 
S3 or new/worsening rales – no(0)/yes(1) 
 
New or worsening MR murmur – no(0)/yes(1) 
 
ECG changes: 
ST depression more than or equal to 0.5mm 
T inversion more than or equal to 0.3mv 
Bundle branch block –new or presumed new – no(0)/ yes(1) 
Sustained VT – no(0)/ yes(1) 
No ECG changes 
 
Cardiac markers:  
Increased Trop I or CK-MB – no(0)/ yes(1) 
 
ECHO: 
          RWMA- no(0)/ yes(1) 
          MR- no(0)/ yes(1) 
          LV dysfunction - no(0)/ yes(1) 
 
GFR <60ml/min– no(0)/ yes(1) 
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Events in 1 week: 
Death  
      Immediate cause of death 
      Time interval between presentation and death 
       PCI done or not  
      Co-morbidities 
 
Recurrence of angina after the initiation of treatment 
                Time interval from initiation of treatment 
                Treatment received for refractory angina 
Re- infarction 
                 Time interval from initiation of treatment 
                 Treatment received for re-infarction 
Bleeding - no(0)/ yes(1) 
                  Minor bleeding- no(0)/ yes(1) 
                  Major bleeding – no(1)/yes(1) 
                  Managed by –  
Stroke - no(0)/ yes(1) 
              Time interval after initiation of treatment  
PCI in 1 week 
            Ischemia driven - no(0)/ yes(1) 
            Other indications 
             Angiogram findings 
             BMS/DES 
             GP IIb/IIIa  
             Post- PCI events 
CABG in 1 week – indication 
                                Time interval between presentation and surgery                                           
 
Duration of hospital stay 
 
Treatment received: 
Aspirin – no(0)/ yes(1) 
Clopidogrel – no(0)/ yes(1) 
Statin – no(0)/ yes(1) 
Betablocker- no(0)/ yes(1) 
ACEI/ARB -- no(0)/ yes(1) 
 
Fondaparinux:  
                 No. of days of treatment with fondaparinux – 5 days (1)/ more than 5 days(2) 
 
Follow up visit at 1 week - no(0)/ yes(1) 
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30 day events: 
 
Death  
      Immediate cause of death 
      Time interval between initial event and death 
       PCI done or not  
      Co-morbidities 
 
Recurrence of angina after completion of treatment with fondaparinux 
       Time interval after completion of treatment with fondaparinux 
        Treatment received for refractory angina 
Re- infarction 
          Time interval after completion of treatment with fondaparinux  
        Treatment for re-infarction 
Bleeding - no(0)/ yes(1) 
                  Time interval after completion of treatment with fondaparinux  
 
                  Minor bleeding- no(0)/ yes(1) 
                  Major bleeding – no(1)/yes(1) 
                  Managed by –  
Stroke - no(0)/ yes(1),  time interval after completion of treatment with fondaparinux 
PCI within 30 days 
            Ischemia driven - no(0)/ yes(1) 
            Other indications 
             Angiogram findings 
             BMS/DES 
             GP IIb/IIIa  
             Post- PCI events 
CABG within 30 days– indication 
                                Time interval between presentation and surgery  
 
Follow up visit at 30 day - no(0)/ yes(1)                                        
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Glossary for master chart 
 
hospno               hospital number 
duration              duration of symptoms 
puledma              pulmonary edema 
tottimi                  total TIMI score 
timilow                TIMI low risk 
timiinter               TIMI intermediate risk 
timihigh               TIMI high risk 
priormi                 prior myocardial infarction 
priorvasc              prior revscularization 
dm                       diabetes mellitus 
ecgchang             ECG changes 
Ua_nstem            admission diagnosis – UA/NSTEMI 
wk1comp             composite endpoints at 1 week 
wk1death             death at 1 week 
wk1MI                  myocardial infarction at 1 week 
wk1ri                    refractory ischemia at 1 week 
mon1comp           composite endpoints at 1 month 
mon1death           death at 1 month 
mon1mi                myocardial infarction at 1month 
mon1ri                  refractory ischemia at 1 month 
inhopproc             procedure during the index hospitalization 
pciwk1                  PCI in 1 week 
pcimon1               PCI in 1 month 
cabg                     CABG 
renalfail                renal failure 
lvdys                     LV dysfunction 
asp1w                   aspirin at 1week 
clop1w                  clopidogrel at 1 week 
bb1w                     betablocker at 1 week 
ace1w                   ACEI/ARB at 1week 
stat1w                   statin at 1 week 
asp1m                   aspirin at 1month 
clop1m                  clopidogrel at 1 month 
bb1m                     betablocker at 1 month 
ace1m                   ACEI/ARB at 1month 
stat1m                   statin at 1 month 
1 male 
2 female 
each variable If Yes (1) 
 If No (0) 
1 Ua (unstable angina) 
2 NSTEMI 
